Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3349174 | 0.98 | KCNA5 (0.35) | KCNA5PPARGCYP2C9CA1MEN1 | |
| SCHEMBL5342131 | 0.85 | HDAC3 (0.39) | KCNA5PPARGCA1MEN1KMT2A | |
| SCHEMBL28953134 | 0.82 | CHRNB2 (0.40) | — | |
| SCHEMBL27716389 | 0.79 | CYP2D6 (0.38) | KCNA5PPARGCA1MEN1KMT2A | |
| SCHEMBL72463 | 0.79 | MEN1 (0.36) | CYP2C9CA1MEN1KMT2AATM | |
| SCHEMBL13773143 | 0.78 | ALDH1A1 (0.37) | KCNA5PPARGCA1ALDH1A1 | |
| SCHEMBL4766625 | 0.75 | MEN1 (0.40) | CYP2C9CA1MEN1KMT2AATM | |
| SCHEMBL16181065 | 0.74 | PLA2G10 (0.37) | PPARGMEN1KMT2A | |
| SCHEMBL4602875 | 0.73 | FAAH (0.40) | — | |
| SCHEMBL27737214 | 0.73 | TSHR (0.41) | KCNA5PPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| CN-101282725-A | Therapeutic agent for diabetes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | KCNA5 2836/4885PPARG 854/4885CYP2C9 214/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | KCNA5 2836/4885PPARG 854/4885CYP2C9 214/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | KCNA5 2816/4885PPARG 3594/4885CYP2C9 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.